About HAL Allergy Group

State of the art in pharmaceutical development

HAL Allergy Group (HAL Allergy) is a modern leader and innovator in the field of biopharmaceuticals and located at the Bio Science Park in Leiden, The Netherlands. Our focus since 1959 stems from the development, production and distribution of Allergen Immunotherapies for the treatment and prevention of allergic diseases. These immunotherapies are used primarily against common allergies such as hay fever, house dust mite allergy and allergic reactions towards wasp or bee stings. With offices in major European countries, HAL Allergy is one of the European top players, particularly in the field of allergy. We take more than a little pride in our international leading role in the production of allergen extracts, both for therapeutic and diagnostic purposes.

In addition, we have an specific expertise in the area of contract manufacturing with focus on the production of biopharmaceutical products for preclinical and clinical studies.

HAL Allergy originally stems from 'Haarlems Allergenen Laboratorium', a Dutch company set up in Haarlem. The company started as a small laboratory where, on request of several local general practitioners (GPs), extracts were prepared on a named patient basis to treat against allergic reactions. The core business of HAL Allergy was, and still is, the treatment of allergies with specific immunotherapies. Patients' well-being is always our top priority.

From the beginning, HAL Allergy was located in the centre of Haarlem, The Netherlands. In the 1970's HAL Allergy grew to a mid-sized laboratory and expanded into the German market. Germany soon developed into a major export country for HAL Allergy products. Over the years the product portfolio has changed and developed along with its headquarters. In January 2007 HAL Allergy had to start looking for new bigger premises and chose to relocate to the Bio Science Park in Leiden, The Netherlands.

Beside the development and production of allergy vaccines, HAL Allergy started a new business in 2012. This new Contract Manufacturing Organization (CMO), named HALIX, is engaged in the production of biotechnological products for preclinical and clinical studies.

We employ around 300 highly specialized people across various functions. The departments at our headquarters include development, production, quality assurance and control, clinical and registration. Our staff works closely together with leading research institutes. At our locations in Germany, Poland, Austria, Spain and Italy we mainly focus on service and sales activities.

HAL Allergy is a subsidiary of the family owned Droege Group

Droege Group (founded in 1988) is an independent advisory and investment company under full family ownership. The company acts as a specialist for tailor-made transformation programs aiming to enhance corporate value. Droege Group combines its corporate family-run structure and capital strength into a family-equity business model. The group carries out direct investments with its own equity in corporate spin-offs and medium-sized companies in "special situations". With the guiding principle "execution - following the rules of art", the group is a pioneer in execution-oriented corporate development. Droege Group follows a focused investment strategy based on current megatrends (knowledge, connectivity, prevention, demography, specialization, future work, shopping 4.0). Enthusiasm for quality, innovation and speed determines the company’s actions. In recent years Droege Group has successfully positioned itself in domestic and international markets and operates in 30 countries.

More information: www.droege-group.com